ELZONRIS is the first and only approved treatment for BPDCN, a deadly hematologic cancer.1,2
Efficacy measures for previously-treated patients1,3
|Efficacy measures||Previously-treated patients(n=15)|
|CR/CRc rate, % (n)||13% (2)|
|Median duration of
|Not yet reached
|ORR, % (n)||67% (10)|
|Bridge to stem cell
transplantation, % (n)
*CRc = clinical complete response; defined as complete response with residual skin abnormality not indicative of active disease.1
BPDCN = blastic plasmacytoid dendritic cell neoplasm; CR = complete response; ORR = overall response rate.
Explore the baseline characteristics of previously-treated patients in the study
Key baseline demographics in the study reflect the patient population and variable presentation of BPDCN.1,3,4
Baseline characteristics: Previously-treated patients1,3,4
|Male, % (n)||86.7% (13)|
|Female, % (n)||13.3% (2)|
|Median age(min, max)||72 (44, 80)|
|ECOG PS, % (n)|
|BPDCN, % (n)|
|Bone marrow||60.0% (9)|
|Peripheral blood||6.7% (1)|
|Lymph nodes||53.3% (8)|
|Prior treatments, % (n)|
|Radiation therapy||33.3% (5)|
|Stem cell transplantation||26.7% (4)|
ECOG PS = Eastern Cooperative Oncology Group performance status.
Previous lines of therapy1,3,4
|Number of lines||Previously-treated patients, % (n)|
|≥ 4||13% (2)|
- ELZONRIS [prescribing information]. New York, NY, US: Stemline Therapeutics, Inc.; December 2018.
- Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188-202.
- Data on file. Stemline Therapeutics, Inc.
- Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628-1637.